Expertise in
38
conditions

Dr. Miguel A. Islas-Ohlmayer

Hematology | Oncology
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 
Accepting New Patients
Expertise in
38
conditions
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 

Overview

Miguel Islas-Ohlmayer is a Hematologist and an Oncologist practicing medicine in Edgewood, Kentucky.

Dr. Islas-Ohlmayer is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 8 clinical trials. Dr. Islas-Ohlmayer is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Hospital Affiliations

St Elizabeth Florence
St Elizabeth Edgewood
St Elizabeth Ft Thomas
St Elizabeth Grant
St Elizabeth Dearborn Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, Edgewood, KY 41017

Additional Areas of Focus

Dr. Islas-Ohlmayer has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Completed
Publish Date: August 13, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 6 Less Clinical Trials

4 Total Publications

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.
Journal: Blood
Published: April 08, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Expertise in
22
conditions
Dr. Kasiani C. Myers
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Kasiani Myers is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Myers is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Congenital Aplastic Anemia, Fanconi Anemia, Aplastic Anemia, and Bone Marrow Transplant. Dr. Myers is currently accepting new patients.

Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Expertise in
13
conditions
Dr. Russell E. Ware
Hematology | Oncology
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Russell Ware is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Ware is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Anemia, and Splenectomy. Dr. Ware is currently accepting new patients.

Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Expertise in
15
conditions
Dr. Charles T. Quinn
Hematology | Oncology
Referral may be required

Office

3333 Burnet Ave # 7015, 
Cincinnati, OH 
 (9.4 miles away)
513-636-4266
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Quinn is a Hematologist and an Oncologist practicing medicine in Cincinnati, Ohio. Dr. Quinn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Quinn is currently accepting new patients.

Frequently Asked Questions about Dr. Miguel A. Islas-Ohlmayer

How do I make an appointment with Dr. Miguel A. Islas-Ohlmayer?

You can book an appointment with Dr. Miguel A. Islas-Ohlmayer by calling their office at 859-301-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Miguel A. Islas-Ohlmayer a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Miguel A. Islas-Ohlmayer is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Miguel A. Islas-Ohlmayer specialize in?

While Dr. Miguel A. Islas-Ohlmayer is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Multiple Myeloma, and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Miguel A. Islas-Ohlmayer participate in research or clinical trials?

Yes. Dr. Miguel A. Islas-Ohlmayer has published 4 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Miguel A. Islas-Ohlmayer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Miguel A. Islas-Ohlmayer accept my insurance?

Dr. Miguel A. Islas-Ohlmayer accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 859-301-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Islas-Ohlmayer's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile